STOCK TITAN
  1. Home
  2. Sec-filings
  3. IRMD
  4. [Form 4] IRADIMED CORP Insider Trading Activity

IRADIMED director sells 1,419 shares of stock

A director of IRADIMED CORP reported open-market sales totaling 1,419 shares of IRMD stock on September 3, 2026, outside any Rule 10b5-1 trading plan.

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

IRADIMED CORP (IRMD) director Monty K. Allen reported selling a total of 1,419 shares of common stock on September 3, 2026 in open-market or private transactions. The sales included 1,014 shares at a weighted average sale price of $86.44 per share (from trades between $86.36 and $86.54) and 405 shares at $86.35 per share. The filing states these transactions were not made under a Rule 10b5-1 trading plan and does not report Mr. Allen's remaining share holdings.

Positive

  • None.

Negative

  • None.
Insider ALLEN MONTY K
Role Director
Sold 1,419 shs ($123K)
Type Security Shares Price Value
Sale Common Stock F1 1,014 $86.44 $88K
Sale Common Stock 405 $86.35 $35K
Holdings After Transaction: Common Stock — 19,581 shares (Direct)
Footnotes (1)
  1. F1. This transaction was executed in multiple trades at prices ranging from $86.36 to $86.54. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Total shares sold 1,419 shares Common stock sales reported for September 3, 2026
Shares sold in weighted-average block 1,014 shares Part of the September 3, 2026 common stock sale
Weighted average sale price $86.44 per share For the 1,014-share sale executed in multiple trades between $86.36 and $86.54
Additional shares sold 405 shares Second reported sale on September 3, 2026
Sale price for additional block $86.35 per share Price for the 405-share sale on September 3, 2026
weighted average sale price financial
"The price reported above reflects the weighted average sale price."
open market or private transaction financial
"Sale in open market or private transaction"

FAQ

What insider transaction did IRMD report for Monty K. Allen?
IRADIMED CORP reported that director Monty K. Allen sold a total of 1,419 shares of the company’s common stock on September 3, 2026 in open-market or private transactions.

How many IRMD shares did the director sell on September 3, 2026, and at what prices?
On September 3, 2026, Monty K. Allen sold 1,014 shares of IRMD at a weighted average price of $86.44 per share, based on trades between $86.36 and $86.54, and an additional 405 shares at $86.35 per share.

Were the September 3, 2026 IRMD insider sales made under a Rule 10b5-1 trading plan?
No. The filing indicates that the Rule 10b5-1 trading plan checkbox is not marked, so the 1,419-share sale by director Monty K. Allen was not reported as made under a Rule 10b5-1 plan.

Does the Form 4 disclose how many IRMD shares Monty K. Allen holds after the sale?
No. For the transactions reported on September 3, 2026, the Form 4 does not provide a post-transaction share balance for Monty K. Allen; the fields for shares held after each transaction are left blank.

What type of security did the IRMD director sell in this Form 4?
The Form 4 reports that Monty K. Allen sold common stock of IRADIMED CORP. The transactions involved non-derivative holdings, with no options or other derivative securities reported in this filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
ALLEN MONTY K
(Last)(First)(Middle)
C/O IRADIMED CORPORATION
12705 INGENUITY DRIVE
(Street)
ORLANDO FLORIDA 32826
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
IRADIMED CORP [ IRMD ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
09/03/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock09/03/2026S1,014D$86.4419,986(1)D
Common Stock09/03/2026S405D$86.3519,581D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. This transaction was executed in multiple trades at prices ranging from $86.36 to $86.54. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Remarks:
/s/ Monty Allen09/08/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

Keep reading

More on IRMD

Trending in the feed

Open the live feed